SK14232001A3 - Nízkomolekulové inhibítory komplementárnych proteáz - Google Patents

Info

Publication number

SK14232001A3

SK14232001A3 SK1423-2001A SK14232001A SK14232001A3 SK 14232001 A3 SK14232001 A3 SK 14232001A3 SK 14232001 A SK14232001 A SK 14232001A SK 14232001 A3 SK14232001 A3 SK 14232001A3

Authority

SK

Slovakia

Prior art keywords

alkyl

thioph

alkylaryl

cycloalkyl

pyr

Prior art date

1999-04-09

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title abstract description 48
• 230000000295 complement effect Effects 0.000 title abstract description 45
• 102000035195 Peptidases Human genes 0.000 title abstract description 13
• 108091005804 Peptidases Proteins 0.000 title abstract description 13
• 239000004365 Protease Substances 0.000 title abstract description 13
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims abstract description 8
• -1 C1-cycloalkyl Chemical group 0.000 claims description 249
• 229910052739 hydrogen Inorganic materials 0.000 claims description 245
• 229910052799 carbon Inorganic materials 0.000 claims description 235
• 125000000217 alkyl group Chemical group 0.000 claims description 189
• 150000001875 compounds Chemical class 0.000 claims description 132
• 229910052760 oxygen Inorganic materials 0.000 claims description 115
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 100
• 229910052717 sulfur Inorganic materials 0.000 claims description 91
• 125000002877 alkyl aryl group Chemical group 0.000 claims description 87
• 238000002360 preparation method Methods 0.000 claims description 63
• 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 55
• 125000003118 aryl group Chemical group 0.000 claims description 50
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
• 125000001424 substituent group Chemical group 0.000 claims description 33
• 229910052757 nitrogen Inorganic materials 0.000 claims description 32
• 125000001544 thienyl group Chemical group 0.000 claims description 30
• 125000004076 pyridyl group Chemical group 0.000 claims description 28
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 27
• 125000006414 CCl Chemical group ClC* 0.000 claims description 25
• 150000003839 salts Chemical class 0.000 claims description 24
• 239000003814 drug Substances 0.000 claims description 22
• 230000005764 inhibitory process Effects 0.000 claims description 22
• PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 claims description 20
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 20
• 229940002612 prodrug Drugs 0.000 claims description 20
• 239000000651 prodrug Substances 0.000 claims description 20
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 20
• 238000011282 treatment Methods 0.000 claims description 19
• 125000002883 imidazolyl group Chemical group 0.000 claims description 18
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 18
• AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 17
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 16
• 125000002541 furyl group Chemical group 0.000 claims description 16
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 16
• WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 15
• 208000035475 disorder Diseases 0.000 claims description 15
• CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 14
• CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 14
• HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 14
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 14
• 208000014674 injury Diseases 0.000 claims description 12
• 125000001624 naphthyl group Chemical group 0.000 claims description 12
• 229910052698 phosphorus Inorganic materials 0.000 claims description 12
• 208000027418 Wounds and injury Diseases 0.000 claims description 11
• 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims description 10
• 230000006378 damage Effects 0.000 claims description 10
• 125000001072 heteroaryl group Chemical group 0.000 claims description 10
• 210000000056 organ Anatomy 0.000 claims description 9
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 8
• 101150065749 Churc1 gene Proteins 0.000 claims description 8
• ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 8
• 102100038239 Protein Churchill Human genes 0.000 claims description 8
• 208000027866 inflammatory disease Diseases 0.000 claims description 8
• 208000010125 myocardial infarction Diseases 0.000 claims description 7
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
• 125000004432 carbon atom Chemical group C* 0.000 claims description 6
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
• 206010061218 Inflammation Diseases 0.000 claims description 5
• 206010033645 Pancreatitis Diseases 0.000 claims description 5
• 230000004054 inflammatory process Effects 0.000 claims description 5
• 208000028867 ischemia Diseases 0.000 claims description 5
• 208000023275 Autoimmune disease Diseases 0.000 claims description 4
• 206010063837 Reperfusion injury Diseases 0.000 claims description 4
• 206010040047 Sepsis Diseases 0.000 claims description 4
• 206010047115 Vasculitis Diseases 0.000 claims description 4
• 208000003455 anaphylaxis Diseases 0.000 claims description 4
• 230000036961 partial effect Effects 0.000 claims description 4
• 238000011321 prophylaxis Methods 0.000 claims description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
• 208000024827 Alzheimer disease Diseases 0.000 claims description 3
• 206010002199 Anaphylactic shock Diseases 0.000 claims description 3
• 208000027496 Behcet disease Diseases 0.000 claims description 3
• 208000009137 Behcet syndrome Diseases 0.000 claims description 3
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
• 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
• 208000006673 asthma Diseases 0.000 claims description 3
• 206010006451 bronchitis Diseases 0.000 claims description 3
• 208000007451 chronic bronchitis Diseases 0.000 claims description 3
• 208000019069 chronic childhood arthritis Diseases 0.000 claims description 3
• 238000000502 dialysis Methods 0.000 claims description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 3
• 201000006370 kidney failure Diseases 0.000 claims description 3
• 201000006417 multiple sclerosis Diseases 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 208000011580 syndromic disease Diseases 0.000 claims description 3
• 206010043778 thyroiditis Diseases 0.000 claims description 3
• 238000002054 transplantation Methods 0.000 claims description 3
• 238000002689 xenotransplantation Methods 0.000 claims description 3
• 208000000995 spontaneous abortion Diseases 0.000 claims description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 3
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
• 208000032843 Hemorrhage Diseases 0.000 claims 2
• 102000000588 Interleukin-2 Human genes 0.000 claims 2
• 108010002350 Interleukin-2 Proteins 0.000 claims 2
• 201000009906 Meningitis Diseases 0.000 claims 2
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
• 208000034486 Multi-organ failure Diseases 0.000 claims 2
• 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
• 208000004221 Multiple Trauma Diseases 0.000 claims 2
• 208000023637 Multiple injury Diseases 0.000 claims 2
• 206010028372 Muscular weakness Diseases 0.000 claims 2
• 208000012902 Nervous system disease Diseases 0.000 claims 2
• 208000025966 Neurological disease Diseases 0.000 claims 2
• 206010053159 Organ failure Diseases 0.000 claims 2
• 206010037437 Pulmonary thrombosis Diseases 0.000 claims 2
• 239000003124 biologic agent Substances 0.000 claims 2
• 230000002490 cerebral effect Effects 0.000 claims 2
• 206010008118 cerebral infarction Diseases 0.000 claims 2
• 208000026106 cerebrovascular disease Diseases 0.000 claims 2
• 206010014599 encephalitis Diseases 0.000 claims 2
• 230000002757 inflammatory effect Effects 0.000 claims 2
• 230000000302 ischemic effect Effects 0.000 claims 2
• 206010025135 lupus erythematosus Diseases 0.000 claims 2
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
• 230000036473 myasthenia Effects 0.000 claims 2
• 230000009424 thromboembolic effect Effects 0.000 claims 2
• 230000008733 trauma Effects 0.000 claims 2
• 230000002792 vascular Effects 0.000 claims 2
• BYTHORAMAVTDAZ-UHFFFAOYSA-N C1=CC=CC2=CC=CC=C12.O.O.O.O Chemical compound C1=CC=CC2=CC=CC=C12.O.O.O.O BYTHORAMAVTDAZ-UHFFFAOYSA-N 0.000 claims 1
• 208000005107 Premature Birth Diseases 0.000 claims 1
• 239000012050 conventional carrier Substances 0.000 claims 1
• 230000002269 spontaneous effect Effects 0.000 claims 1
• 239000000126 substance Substances 0.000 abstract description 14
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 abstract description 3
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 abstract description 3
• 239000004074 complement inhibitor Substances 0.000 abstract description 2
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 200
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 186
• 239000000243 solution Substances 0.000 description 130
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 129
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 100
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
• 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 80
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 70
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 59
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 44
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
• 150000003254 radicals Chemical class 0.000 description 41
• 230000002829 reductive effect Effects 0.000 description 38
• 239000000203 mixture Substances 0.000 description 37
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 34
• 239000000843 powder Substances 0.000 description 34
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 33
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 33
• 238000006243 chemical reaction Methods 0.000 description 32
• 239000002904 solvent Substances 0.000 description 30
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
• 230000004154 complement system Effects 0.000 description 26
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
• 125000006239 protecting group Chemical group 0.000 description 24
• 238000003756 stirring Methods 0.000 description 24
• 238000004440 column chromatography Methods 0.000 description 23
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
• 238000004809 thin layer chromatography Methods 0.000 description 22
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
• 239000000872 buffer Substances 0.000 description 21
• 230000037361 pathway Effects 0.000 description 21
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
• 229960000583 acetic acid Drugs 0.000 description 20
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
• 150000001408 amides Chemical group 0.000 description 19
• 239000003921 oil Substances 0.000 description 19
• 239000012071 phase Substances 0.000 description 19
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
• 239000011541 reaction mixture Substances 0.000 description 18
• 239000011347 resin Substances 0.000 description 18
• 229920005989 resin Polymers 0.000 description 18
• 239000000758 substrate Substances 0.000 description 18
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
• 239000013078 crystal Substances 0.000 description 17
• 238000005160 1H NMR spectroscopy Methods 0.000 description 16
• 230000015572 biosynthetic process Effects 0.000 description 16
• 210000004027 cell Anatomy 0.000 description 16
• 239000003480 eluent Substances 0.000 description 16
• 239000000047 product Substances 0.000 description 16
• 230000004913 activation Effects 0.000 description 15
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
• 238000003786 synthesis reaction Methods 0.000 description 15
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
• FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 14
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 14
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 14
• 210000002966 serum Anatomy 0.000 description 14
• 239000011734 sodium Substances 0.000 description 14
• 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 14
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 12
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 12
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 12
• 150000001409 amidines Chemical class 0.000 description 12
• 230000009089 cytolysis Effects 0.000 description 12
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 12
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 12
• 239000011550 stock solution Substances 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 229940009550 c1 esterase inhibitor Drugs 0.000 description 11
• 238000001704 evaporation Methods 0.000 description 11
• 230000008020 evaporation Effects 0.000 description 11
• 239000000543 intermediate Substances 0.000 description 11
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
• 235000019341 magnesium sulphate Nutrition 0.000 description 11
• 239000012074 organic phase Substances 0.000 description 11
• 238000000746 purification Methods 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
• 239000003153 chemical reaction reagent Substances 0.000 description 10
• 239000002244 precipitate Substances 0.000 description 10
• 239000011780 sodium chloride Substances 0.000 description 10
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
• 239000002253 acid Substances 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 239000012043 crude product Substances 0.000 description 9
• 150000002148 esters Chemical class 0.000 description 9
• 239000007789 gas Substances 0.000 description 9
• 238000011534 incubation Methods 0.000 description 9
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
• 230000024203 complement activation Effects 0.000 description 8
• 238000005259 measurement Methods 0.000 description 8
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
• 229960002319 barbital Drugs 0.000 description 7
• 230000000694 effects Effects 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 238000000034 method Methods 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 6
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• 239000007983 Tris buffer Substances 0.000 description 6
• 238000002835 absorbance Methods 0.000 description 6
• 229910021529 ammonia Inorganic materials 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 239000008346 aqueous phase Substances 0.000 description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
• 230000008878 coupling Effects 0.000 description 6
• 238000010168 coupling process Methods 0.000 description 6
• 238000005859 coupling reaction Methods 0.000 description 6
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
• 238000011156 evaluation Methods 0.000 description 6
• 239000008273 gelatin Substances 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 235000019322 gelatine Nutrition 0.000 description 6
• 235000011852 gelatine desserts Nutrition 0.000 description 6
• 239000012362 glacial acetic acid Substances 0.000 description 6
• 229910000037 hydrogen sulfide Inorganic materials 0.000 description 6
• 230000007062 hydrolysis Effects 0.000 description 6
• 238000006460 hydrolysis reaction Methods 0.000 description 6
• 150000002825 nitriles Chemical group 0.000 description 6
• 235000018102 proteins Nutrition 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 108090000623 proteins and genes Proteins 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• XCAQIUOFDMREBA-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=O)OC(C)(C)C XCAQIUOFDMREBA-UHFFFAOYSA-N 0.000 description 6
• HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 239000012267 brine Substances 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 239000000706 filtrate Substances 0.000 description 5
• 239000012467 final product Substances 0.000 description 5
• 230000004963 pathophysiological condition Effects 0.000 description 5
• 239000003208 petroleum Substances 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
• KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 238000004364 calculation method Methods 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 238000001816 cooling Methods 0.000 description 4
• 238000002425 crystallisation Methods 0.000 description 4
• 230000008025 crystallization Effects 0.000 description 4
• 125000004093 cyano group Chemical group *C#N 0.000 description 4
• 238000010511 deprotection reaction Methods 0.000 description 4
• 239000002274 desiccant Substances 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 210000003743 erythrocyte Anatomy 0.000 description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
• 150000002500 ions Chemical class 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
• 239000000741 silica gel Substances 0.000 description 4
• 229910002027 silica gel Inorganic materials 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 3
• IADUEWIQBXOCDZ-UHFFFAOYSA-N (2S)-azetidine-2-carboxylic acid Natural products OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 3
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
• GVKCMDVUXSQDJY-UHFFFAOYSA-N 2-[5-(aminomethyl)-1,3-thiazol-2-yl]guanidine;dihydrochloride Chemical compound Cl.Cl.NCC1=CN=C(NC(N)=N)S1 GVKCMDVUXSQDJY-UHFFFAOYSA-N 0.000 description 3
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 3
• NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
• 229910004373 HOAc Inorganic materials 0.000 description 3
• 206010019280 Heart failures Diseases 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 241001494479 Pecora Species 0.000 description 3
• 108010022999 Serine Proteases Proteins 0.000 description 3
• 102000012479 Serine Proteases Human genes 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 3
• 150000001299 aldehydes Chemical class 0.000 description 3
• QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• KBPUBGDVTAGNRI-UHFFFAOYSA-N aminomethyl cyclohexanecarboxylate Chemical compound NCOC(=O)C1CCCCC1 KBPUBGDVTAGNRI-UHFFFAOYSA-N 0.000 description 3
• 150000008064 anhydrides Chemical class 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 230000018044 dehydration Effects 0.000 description 3
• 238000006297 dehydration reaction Methods 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 238000001035 drying Methods 0.000 description 3
• 125000004185 ester group Chemical group 0.000 description 3
• NCCMCRFYSZRBBG-UHFFFAOYSA-N ethyl 5-amino-4-cyano-3-methylthiophene-2-carboxylate Chemical compound CCOC(=O)C=1SC(N)=C(C#N)C=1C NCCMCRFYSZRBBG-UHFFFAOYSA-N 0.000 description 3
• 239000002024 ethyl acetate extract Substances 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
• 239000005457 ice water Substances 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 125000001041 indolyl group Chemical group 0.000 description 3
• 150000004702 methyl esters Chemical class 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 3
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 3
• 239000012312 sodium hydride Substances 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• 238000010532 solid phase synthesis reaction Methods 0.000 description 3
• 241000894007 species Species 0.000 description 3
• GSIBTIUXYYFCPU-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(CBr)C=C1 GSIBTIUXYYFCPU-UHFFFAOYSA-N 0.000 description 3
• PFNACHMSMQBNMB-UHFFFAOYSA-N tert-butyl N-[2-(aminomethyl)-4-methylthiophene-3-carbothioyl]carbamate Chemical compound NCC=1SC=C(C=1C(NC(=O)OC(C)(C)C)=S)C PFNACHMSMQBNMB-UHFFFAOYSA-N 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
• QSUXZIPXYDQFCX-SNVBAGLBSA-N (2r)-2-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)C1CCCCC1 QSUXZIPXYDQFCX-SNVBAGLBSA-N 0.000 description 2
• LLAKGSVMNLYWAQ-NUBCRITNSA-N (2r)-3-methyl-2-(methylamino)butanoic acid;hydrochloride Chemical compound Cl.CN[C@H](C(C)C)C(O)=O LLAKGSVMNLYWAQ-NUBCRITNSA-N 0.000 description 2
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 2
• MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 2
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
• NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 2
• LRHRHAWNXCGABU-UHFFFAOYSA-N 2-(cyclopentylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCC1 LRHRHAWNXCGABU-UHFFFAOYSA-N 0.000 description 2
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
• PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
• VJLXRRTVABNKJA-UHFFFAOYSA-N 4-chloro-5-(hydroxymethyl)thiophene-3-carbonitrile Chemical compound OCC=1SC=C(C#N)C=1Cl VJLXRRTVABNKJA-UHFFFAOYSA-N 0.000 description 2
• BVFSVQRHFKTEMM-UHFFFAOYSA-N 4-chloro-5-formylthiophene-3-carbonitrile Chemical compound ClC1=C(C=O)SC=C1C#N BVFSVQRHFKTEMM-UHFFFAOYSA-N 0.000 description 2
• GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 2
• OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
• VYSCDLZIYMYEOY-UHFFFAOYSA-N 5-(aminomethyl)-3-methylthiophene-2-carbonitrile Chemical compound CC=1C=C(CN)SC=1C#N VYSCDLZIYMYEOY-UHFFFAOYSA-N 0.000 description 2
• OSDGTEZAPBYUQX-UHFFFAOYSA-N 5-(aminomethyl)thiophene-3-carbonitrile Chemical compound NCC1=CC(C#N)=CS1 OSDGTEZAPBYUQX-UHFFFAOYSA-N 0.000 description 2
• GRWJYBPRAOPQPX-UHFFFAOYSA-N 5-(aminomethyl)thiophene-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.NCC1=CC(C(N)=N)=CS1 GRWJYBPRAOPQPX-UHFFFAOYSA-N 0.000 description 2
• LYBHGFYIJPQIKP-UHFFFAOYSA-N 5-(bromomethyl)-3-methylthiophene-2-carbonitrile Chemical compound CC=1C=C(CBr)SC=1C#N LYBHGFYIJPQIKP-UHFFFAOYSA-N 0.000 description 2
• AZVCRELZXHPNJG-UHFFFAOYSA-N 5-(bromomethyl)-4-chlorothiophene-3-carbonitrile Chemical compound ClC1=C(CBr)SC=C1C#N AZVCRELZXHPNJG-UHFFFAOYSA-N 0.000 description 2
• GNGBYGNCYWGVIW-UHFFFAOYSA-N 5-(bromomethyl)-4-methylthiophene-3-carbonitrile Chemical compound CC1=C(CBr)SC=C1C#N GNGBYGNCYWGVIW-UHFFFAOYSA-N 0.000 description 2
• SBAVSUHIXDKUMH-UHFFFAOYSA-N 5-(hydroxymethyl)-3-methylthiophene-2-carbonitrile Chemical compound CC=1C=C(CO)SC=1C#N SBAVSUHIXDKUMH-UHFFFAOYSA-N 0.000 description 2
• IGBCJVUIPUDISK-UHFFFAOYSA-N 5-(hydroxymethyl)-4-methylthiophene-3-carbonitrile Chemical compound CC1=C(CO)SC=C1C#N IGBCJVUIPUDISK-UHFFFAOYSA-N 0.000 description 2
• NEPGMLCZUNJRSN-UHFFFAOYSA-N 5-formyl-3-methylthiophene-2-carbonitrile Chemical compound CC=1C=C(C=O)SC=1C#N NEPGMLCZUNJRSN-UHFFFAOYSA-N 0.000 description 2
• ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000208199 Buxus sempervirens Species 0.000 description 2
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
• 102000055157 Complement C1 Inhibitor Human genes 0.000 description 2
• 108700040183 Complement C1 Inhibitor Proteins 0.000 description 2
• 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 2
• 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 2
• 102000000989 Complement System Proteins Human genes 0.000 description 2
• 108010069112 Complement System Proteins Proteins 0.000 description 2
• 108090000056 Complement factor B Proteins 0.000 description 2
• 102000003712 Complement factor B Human genes 0.000 description 2
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 2
• 102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 description 2
• 102100026553 Mannose-binding protein C Human genes 0.000 description 2
• 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 238000006845 Michael addition reaction Methods 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 206010033647 Pancreatitis acute Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• SRXKIZXIRHMPFW-UHFFFAOYSA-N [4-[6-[amino(azaniumylidene)methyl]naphthalen-2-yl]oxycarbonylphenyl]-(diaminomethylidene)azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=CC(N=C([NH3+])N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C([NH3+])=N)C2=C1 SRXKIZXIRHMPFW-UHFFFAOYSA-N 0.000 description 2
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
• 206010000210 abortion Diseases 0.000 description 2
• 231100000176 abortion Toxicity 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 201000003229 acute pancreatitis Diseases 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• 230000003024 amidolytic effect Effects 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 150000001805 chlorine compounds Chemical class 0.000 description 2
• 229930016911 cinnamic acid Natural products 0.000 description 2
• 235000013985 cinnamic acid Nutrition 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
• 229940043279 diisopropylamine Drugs 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• 238000004821 distillation Methods 0.000 description 2
• 238000002451 electron ionisation mass spectrometry Methods 0.000 description 2
• NMCZTUHUUFFVHP-UHFFFAOYSA-N ethyl 4-cyano-3-methylthiophene-2-carboxylate Chemical compound CCOC(=O)C=1SC=C(C#N)C=1C NMCZTUHUUFFVHP-UHFFFAOYSA-N 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
• 230000002949 hemolytic effect Effects 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 238000007327 hydrogenolysis reaction Methods 0.000 description 2
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 229940126601 medicinal product Drugs 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 125000004492 methyl ester group Chemical group 0.000 description 2
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• 230000001991 pathophysiological effect Effects 0.000 description 2
• 230000007310 pathophysiology Effects 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 230000001376 precipitating effect Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 238000006268 reductive amination reaction Methods 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 239000003001 serine protease inhibitor Substances 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000010972 statistical evaluation Methods 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• YKSAJNAZUKXQQB-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)-5-cyano-4-methylthiophene-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=C(C(=C(S1)C#N)C)CN YKSAJNAZUKXQQB-UHFFFAOYSA-N 0.000 description 2
• IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
• 239000012414 tert-butyl nitrite Substances 0.000 description 2
• 238000010998 test method Methods 0.000 description 2
• JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 description 2
• FIWAQJRIROPAEC-IBGZPJMESA-N thiobenzyl benzyloxycarbonyl-L-lysinate Chemical compound N([C@@H](CCCCN)C(=O)SCC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 FIWAQJRIROPAEC-IBGZPJMESA-N 0.000 description 2
• NZYMHENLAOOTLV-UHFFFAOYSA-N thiophen-2-ylmethylazanium;chloride Chemical compound Cl.NCC1=CC=CS1 NZYMHENLAOOTLV-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
• LCEIGNVIDJNUGF-UHFFFAOYSA-N (2,5-dichlorophenyl)methanol Chemical compound OCC1=CC(Cl)=CC=C1Cl LCEIGNVIDJNUGF-UHFFFAOYSA-N 0.000 description 1
• SHWPIYPTNIBVPS-CQSZACIVSA-N (2r)-3-methyl-2-[[4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]methylamino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)NCC1=CC=C(C(=O)OC(C)(C)C)C=C1 SHWPIYPTNIBVPS-CQSZACIVSA-N 0.000 description 1
• QPOHINNWVADWCQ-CQSZACIVSA-N (2r)-3-methyl-2-[[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]methylsulfonylamino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)NS(=O)(=O)CC1=CC=C(NC(=O)OC(C)(C)C)C=C1 QPOHINNWVADWCQ-CQSZACIVSA-N 0.000 description 1
• ICZOJKLCAVRCML-OAHLLOKOSA-N (2r)-3-methyl-2-[methyl-[[4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]methyl]amino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)N(C)CC1=CC=C(C(=O)OC(C)(C)C)C=C1 ICZOJKLCAVRCML-OAHLLOKOSA-N 0.000 description 1
• ZBVSOXYHOSSTIL-OAHLLOKOSA-N (2r)-3-methyl-2-[methyl-[[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]methylsulfonyl]amino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)N(C)S(=O)(=O)CC1=CC=C(NC(=O)OC(C)(C)C)C=C1 ZBVSOXYHOSSTIL-OAHLLOKOSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
• WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
• CNPSFBUUYIVHAP-AKGZTFGVSA-N (2s)-3-methylpyrrolidine-2-carboxylic acid Chemical compound CC1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-AKGZTFGVSA-N 0.000 description 1
• ZPBIYZHGBPBZCK-VKHMYHEASA-N (2s)-4,4-difluoropyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)[C@@H]1CC(F)(F)CN1 ZPBIYZHGBPBZCK-VKHMYHEASA-N 0.000 description 1
• YNSYWEFVEIFJPZ-AKGZTFGVSA-N (2s)-5-methylpyrrolidine-2-carboxylic acid Chemical compound CC1CC[C@@H](C(O)=O)N1 YNSYWEFVEIFJPZ-AKGZTFGVSA-N 0.000 description 1
• CQYBNXGHMBNGCG-FXQIFTODSA-N (2s,3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-1-ium-2-carboxylate Chemical compound C1CCC[C@@H]2[NH2+][C@H](C(=O)[O-])C[C@@H]21 CQYBNXGHMBNGCG-FXQIFTODSA-N 0.000 description 1
• CAXRPEAFHWDFTD-UHFFFAOYSA-N (4-nitrophenyl)methanesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CS(Cl)(=O)=O)C=C1 CAXRPEAFHWDFTD-UHFFFAOYSA-N 0.000 description 1
• MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
• AHKODUHAIHWAFQ-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1.C1=CC=C2C(C(=O)O)NCCC2=C1 AHKODUHAIHWAFQ-UHFFFAOYSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
• ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 1
• UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
• ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
• WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• XNONHUBNQKPICE-UHFFFAOYSA-N 1-hydroxynaphthalene-2-carboximidamide Chemical class C1=CC=CC2=C(O)C(C(=N)N)=CC=C21 XNONHUBNQKPICE-UHFFFAOYSA-N 0.000 description 1
• RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• WSMBEQKQQASPPL-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole-1-carboxylic acid Chemical compound C1CCCC2C(C(=O)O)NCC21 WSMBEQKQQASPPL-UHFFFAOYSA-N 0.000 description 1
• OFKFBEJYOHXPIA-UHFFFAOYSA-N 2,3-dihydro-1h-isoindol-2-ium-1-carboxylate Chemical compound C1=CC=C2C(C(=O)O)NCC2=C1 OFKFBEJYOHXPIA-UHFFFAOYSA-N 0.000 description 1
• OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
• KKFAAUVAMMLJDF-UHFFFAOYSA-N 2-(aminomethyl)-1,3-thiazole-4-carbothioamide Chemical compound NCC1=NC(C(N)=S)=CS1 KKFAAUVAMMLJDF-UHFFFAOYSA-N 0.000 description 1
• NPLBBQAAYSJEMO-UHFFFAOYSA-N 2-(cycloheptylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCCCC1 NPLBBQAAYSJEMO-UHFFFAOYSA-N 0.000 description 1
• FRYOUKNFWFXASU-UHFFFAOYSA-N 2-(methylamino)acetic acid Chemical compound CNCC(O)=O.CNCC(O)=O FRYOUKNFWFXASU-UHFFFAOYSA-N 0.000 description 1
• ITSKWKZDPHAQNK-UHFFFAOYSA-N 2-acetyl-5,5-dimethylcyclohexane-1,3-dione Chemical compound CC(=O)C1C(=O)CC(C)(C)CC1=O ITSKWKZDPHAQNK-UHFFFAOYSA-N 0.000 description 1
• XIZSUYSWKGAOCN-UHFFFAOYSA-N 2-amino-4-chloro-5-formylthiophene-3-carbonitrile Chemical compound NC=1SC(C=O)=C(Cl)C=1C#N XIZSUYSWKGAOCN-UHFFFAOYSA-N 0.000 description 1
• MXHKOHWUQAULOV-UHFFFAOYSA-N 2-azaniumyl-4-cyclohexylbutanoate Chemical compound OC(=O)C(N)CCC1CCCCC1 MXHKOHWUQAULOV-UHFFFAOYSA-N 0.000 description 1
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
• XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
• JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
• YWFGCYQKXLSDKT-UHFFFAOYSA-N 3-(2,3-diethylphenyl)pentan-3-ylazanium;chloride Chemical compound [Cl-].CCC1=CC=CC(C([NH3+])(CC)CC)=C1CC YWFGCYQKXLSDKT-UHFFFAOYSA-N 0.000 description 1
• HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
• BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
• WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
• SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
• IEDIKTABXQYWBL-UHFFFAOYSA-N 3-aminopropanoic acid Chemical compound NCCC(O)=O.NCCC(O)=O IEDIKTABXQYWBL-UHFFFAOYSA-N 0.000 description 1
• FPGDDWCTBDGPAD-UHFFFAOYSA-N 3-chlorothiophene-2-carbonitrile Chemical compound ClC=1C=CSC=1C#N FPGDDWCTBDGPAD-UHFFFAOYSA-N 0.000 description 1
• PUKKVMZZENXNSR-UHFFFAOYSA-N 3-chlorothiophene-2-carboxamide Chemical compound NC(=O)C=1SC=CC=1Cl PUKKVMZZENXNSR-UHFFFAOYSA-N 0.000 description 1
• ALZHYEITUZEZMT-UHFFFAOYSA-N 3-methylthiophene-2-carbonitrile Chemical compound CC=1C=CSC=1C#N ALZHYEITUZEZMT-UHFFFAOYSA-N 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• LFIWXXXFJFOECP-UHFFFAOYSA-N 4-(aminomethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 description 1
• QNJHTLTUBNXLFS-UHFFFAOYSA-N 4-(bromomethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(CBr)C=C1 QNJHTLTUBNXLFS-UHFFFAOYSA-N 0.000 description 1
• DDSXIDHLKARTSS-UHFFFAOYSA-N 4-(bromomethyl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(CBr)C=C1 DDSXIDHLKARTSS-UHFFFAOYSA-N 0.000 description 1
• VWSFZYXXQDKXKQ-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxy]benzaldehyde Chemical compound CC(C)(C)OC1=CC=C(C=O)C=C1 VWSFZYXXQDKXKQ-UHFFFAOYSA-N 0.000 description 1
• KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
• IFQUPKAISSPFTE-UHFFFAOYSA-N 4-benzoylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)C1=CC=CC=C1 IFQUPKAISSPFTE-UHFFFAOYSA-N 0.000 description 1
• PTCSSXYPZOFISK-UHFFFAOYSA-N 4-chlorosulfonylbenzoic acid Chemical compound OC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 PTCSSXYPZOFISK-UHFFFAOYSA-N 0.000 description 1
• ABTQIHJLNPRSFI-UHFFFAOYSA-N 5-(aminomethyl)-3-chlorothiophene-2-carbonitrile;hydrochloride Chemical compound Cl.NCC1=CC(Cl)=C(C#N)S1 ABTQIHJLNPRSFI-UHFFFAOYSA-N 0.000 description 1
• PNBXOHLVMHYSNL-UHFFFAOYSA-N 5-(aminomethyl)-3-methylthiophene-2-carbonitrile;hydrochloride Chemical compound Cl.CC=1C=C(CN)SC=1C#N PNBXOHLVMHYSNL-UHFFFAOYSA-N 0.000 description 1
• JCQLHILYDSQNTL-UHFFFAOYSA-N 5-(aminomethyl)-4-chlorothiophene-3-carbothioamide Chemical compound NCC=1SC=C(C(N)=S)C=1Cl JCQLHILYDSQNTL-UHFFFAOYSA-N 0.000 description 1
• PZBPERMHYKZOQE-UHFFFAOYSA-N 5-(aminomethyl)-4-chlorothiophene-3-carbothioamide;hydrochloride Chemical compound Cl.NCC=1SC=C(C(N)=S)C=1Cl PZBPERMHYKZOQE-UHFFFAOYSA-N 0.000 description 1
• ZSHWHOXETLPOKC-UHFFFAOYSA-N 5-(aminomethyl)-4-methylthiophene-3-carbothioamide Chemical compound CC1=C(CN)SC=C1C(N)=S ZSHWHOXETLPOKC-UHFFFAOYSA-N 0.000 description 1
• OYOJEAMXMAZVPP-UHFFFAOYSA-N 5-(aminomethyl)-4-methylthiophene-3-carbothioamide;hydrochloride Chemical compound Cl.CC1=C(CN)SC=C1C(N)=S OYOJEAMXMAZVPP-UHFFFAOYSA-N 0.000 description 1
• AIBYYQLJOMFINU-UHFFFAOYSA-N 5-(aminomethyl)furan-2-carbonitrile Chemical compound NCC1=CC=C(C#N)O1 AIBYYQLJOMFINU-UHFFFAOYSA-N 0.000 description 1
• XCTNQPYJQUEHLF-UHFFFAOYSA-N 5-(aminomethyl)furan-3-carbonitrile Chemical compound NCC1=CC(C#N)=CO1 XCTNQPYJQUEHLF-UHFFFAOYSA-N 0.000 description 1
• FHYNZXSHHPBOBK-UHFFFAOYSA-N 5-(aminomethyl)thiophene-2-carbonitrile Chemical compound NCC1=CC=C(C#N)S1 FHYNZXSHHPBOBK-UHFFFAOYSA-N 0.000 description 1
• IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
• LSCIGPJVGLAGMQ-UHFFFAOYSA-N 5-aminothiophene-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)C1=CSC(N)=C1 LSCIGPJVGLAGMQ-UHFFFAOYSA-N 0.000 description 1
• WNXNUPJZWYOKMW-UHFFFAOYSA-N 5-bromopentanoic acid Chemical compound OC(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-N 0.000 description 1
• BYHDDXPKOZIZRV-UHFFFAOYSA-N 5-phenylpentanoic acid Chemical compound OC(=O)CCCCC1=CC=CC=C1 BYHDDXPKOZIZRV-UHFFFAOYSA-N 0.000 description 1
• XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
• KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
• WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
• KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
• BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
• CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
• OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 206010002388 Angina unstable Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• IADUEWIQBXOCDZ-VKHMYHEASA-N Azetidine-2-carboxylic acid Natural products OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010070545 Bacterial translocation Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 241000537222 Betabaculovirus Species 0.000 description 1
• NJTZSWLQBQJUHK-UHFFFAOYSA-N CCCP(=O)=O Chemical compound CCCP(=O)=O NJTZSWLQBQJUHK-UHFFFAOYSA-N 0.000 description 1
• 102100022002 CD59 glycoprotein Human genes 0.000 description 1
• WBUQNPRAVJQENP-GFCCVEGCSA-N CN([C@H](C(C)C)C(=O)O)S(=O)(=O)CC1=CC=C(C=C1)N Chemical compound CN([C@H](C(C)C)C(=O)O)S(=O)(=O)CC1=CC=C(C=C1)N WBUQNPRAVJQENP-GFCCVEGCSA-N 0.000 description 1
• YDMHYPCIKRJGRO-GFCCVEGCSA-N CN([C@H](C(C)C)C(=O)O)S(=O)(=O)CC1=CC=C(C=C1)[N+](=O)[O-] Chemical compound CN([C@H](C(C)C)C(=O)O)S(=O)(=O)CC1=CC=C(C=C1)[N+](=O)[O-] YDMHYPCIKRJGRO-GFCCVEGCSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 101710172562 Cobra venom factor Proteins 0.000 description 1
• 108010024114 Complement 3b Receptors Proteins 0.000 description 1
• 102000015612 Complement 3b Receptors Human genes 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
• COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• 229940122601 Esterase inhibitor Drugs 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 206010019860 Hereditary angioedema Diseases 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 241001484259 Lacuna Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 206010027202 Meningitis bacterial Diseases 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
• OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 241000220010 Rhode Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 229940122055 Serine protease inhibitor Drugs 0.000 description 1
• 101710102218 Serine protease inhibitor Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 239000012317 TBTU Substances 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
• 206010060872 Transplant failure Diseases 0.000 description 1
• RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 206010053648 Vascular occlusion Diseases 0.000 description 1
• 239000003875 Wang resin Substances 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 229920000392 Zymosan Polymers 0.000 description 1
• LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
• OGALXJIOJZXBBP-UHFFFAOYSA-N [4-(chloromethyl)phenyl]methanol Chemical compound OCC1=CC=C(CCl)C=C1 OGALXJIOJZXBBP-UHFFFAOYSA-N 0.000 description 1
• NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
• XAXXTYXMWOFKLW-UHFFFAOYSA-N [C-]1=CC=[NH+]1 Chemical compound [C-]1=CC=[NH+]1 XAXXTYXMWOFKLW-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 229960004308 acetylcysteine Drugs 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005261 aspartic acid Drugs 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 201000009904 bacterial meningitis Diseases 0.000 description 1
• 230000007375 bacterial translocation Effects 0.000 description 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
• IKWQWOFXRCUIFT-UHFFFAOYSA-N benzene-1,2-dicarbohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C(=O)NN IKWQWOFXRCUIFT-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000003293 cardioprotective effect Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 102000006834 complement receptors Human genes 0.000 description 1
• 108010047295 complement receptors Proteins 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
• UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• OKGXJRGLYVRVNE-UHFFFAOYSA-N diaminomethylidenethiourea Chemical compound NC(N)=NC(N)=S OKGXJRGLYVRVNE-UHFFFAOYSA-N 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 239000002329 esterase inhibitor Substances 0.000 description 1
• NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
• XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
• 229940093858 ethyl acetoacetate Drugs 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000007941 film coated tablet Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 238000010579 first pass effect Methods 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 239000011491 glass wool Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 150000002357 guanidines Chemical class 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• IEYXUDKJVHYWOM-UHFFFAOYSA-N methyl 1,3-thiazolidine-2-carboxylate Chemical compound COC(=O)C1NCCS1 IEYXUDKJVHYWOM-UHFFFAOYSA-N 0.000 description 1
• YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
• GDUIXXVCMDFRFQ-UHFFFAOYSA-N methyl 6-isocyanatohexanoate Chemical compound COC(=O)CCCCCN=C=O GDUIXXVCMDFRFQ-UHFFFAOYSA-N 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 229950009865 nafamostat Drugs 0.000 description 1
• 210000001989 nasopharynx Anatomy 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229940116315 oxalic acid Drugs 0.000 description 1
• QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• QCXJEYYXVJIFCE-UHFFFAOYSA-N para-acetamidobenzoic acid Natural products CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 229950009215 phenylbutanoic acid Drugs 0.000 description 1
• XNERWVPQCYSMLC-UHFFFAOYSA-N phenylpropiolic acid Chemical compound OC(=O)C#CC1=CC=CC=C1 XNERWVPQCYSMLC-UHFFFAOYSA-N 0.000 description 1
• 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 238000009790 rate-determining step (RDS) Methods 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 238000005932 reductive alkylation reaction Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 238000009118 salvage therapy Methods 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
• FWVVBSNKXPFYMT-UHFFFAOYSA-N tert-butyl 3-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(CBr)=C1 FWVVBSNKXPFYMT-UHFFFAOYSA-N 0.000 description 1
• GCSSHHMFETYPQE-UHFFFAOYSA-N tert-butyl 4-(chlorosulfonylmethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(CS(Cl)(=O)=O)C=C1 GCSSHHMFETYPQE-UHFFFAOYSA-N 0.000 description 1
• ONSQJICPTKNNAN-UHFFFAOYSA-N tert-butyl 5-(aminomethyl)-3-chloro-4-cyanothiophene-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=C(C(=C(S1)CN)C#N)Cl ONSQJICPTKNNAN-UHFFFAOYSA-N 0.000 description 1
• RQNKPVPXYRSRLO-UHFFFAOYSA-N tert-butyl 5-(aminomethyl)-4-cyano-3-methylthiophene-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=C(C(=C(S1)CN)C#N)C RQNKPVPXYRSRLO-UHFFFAOYSA-N 0.000 description 1
• QENLWMUHMPQWIM-UHFFFAOYSA-N tert-butyl n-[(4-cyanothiophen-2-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC(C#N)=CS1 QENLWMUHMPQWIM-UHFFFAOYSA-N 0.000 description 1
• 150000004685 tetrahydrates Chemical class 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 150000003556 thioamides Chemical class 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
• 208000021331 vascular occlusion disease Diseases 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1